Experimental drug targets MET-Overexpressing lung cancer in early trial
NCT ID NCT04982224
First seen Nov 03, 2025 · Last updated May 24, 2026 · Updated 26 times
Summary
This study tested an experimental drug called REGN5093-M114, alone or with another drug, in people with advanced non-small cell lung cancer (NSCLC) that makes too much MET protein. The goal was to find a safe dose and see if it could shrink tumors. The study was stopped early, and results are not yet available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NSCLC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Henry Ford Hospital, Henry Ford Cancer Institute
Detroit, Michigan, 48202, United States
-
Johns Hopkins Hospital - Clinical Study Location - Skip Viragh Outpatient Cancer Building
Baltimore, Maryland, 21231, United States
-
MUSC Hollings Cancer Center
Charleston, South Carolina, 29425, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Next Virginia
Fairfax, Virginia, 22031, United States
-
Sidney Kimmel Comprehensive Cancer Center - 4F Second Medical Building
Baltimore, Maryland, 21231, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of California Irvine School of Medicine - Suite 400, Room 407
Orange, California, 92868, United States
-
University of Colorado Hospital Anshutz Outpatient Pavillion
Denver, Colorado, 80045, United States
-
University of Pittsburgh Medical Center - Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
Conditions
Explore the condition pages connected to this study.